Status:
COMPLETED
Noninvasive Evaluation of Renal Allograft Fibrosis by MRI
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to validate an MRI method to detect renal fibrosis in patients after kidney transplantation (KT).
Detailed Description
The hypothesis underlying this proposal is that qMT reliably detects development of allograft fibrosis in human subjects after KT. To test this hypothesis, the qMT-derived bound pool fraction will be ...
Eligibility Criteria
Inclusion
- Age 18-80 years
- Recipient of living donor kidney transplantation 4 or 7 years earlier
- Competent and able to provide written informed consent; Ability to comply with protocol
Exclusion
- Patients have clinically significant medical conditions within the prior 6 months before: e.g. myocardial infarction, congestive heart failure, stroke, that would, in the opinion of the investigators, compromise the safety of the patient.
- Severe chronic liver, heart or lung disease
- Undergoing acute rejection
- Contra-indication to biopsy; bleeding disorders
- Chronic infection
- Any active malignancy and undergoing therapy
- Kidney or ureteric stone
- Unable to give valid informed consent
- Known pregnancy or intent to conceive during the study period
- Pacemaker, implantable defibrillator, magnetically active metal fragments, claustrophobia or other contraindication to MRI
- Federal medical center inmates.
- Latex allergy
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2023
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04899167
Start Date
August 1 2021
End Date
August 30 2023
Last Update
October 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905